Clinical trial · Interventional
Radiolabeled Molecules for Medullary Thyroid Cancer
The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer
NCT01915485CI-TRIAL-00023772unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Medullary thyroid cancer is a neuroendocrine tumour. As so, it has somatostatin receptors in its membrane. Furthermore, very little is available to treat patients who have disease progression. The investigators hypothesized that those tumors may respond to 177-Lu-DOTA Tyr3-octreotate which is a ligand to somatostatin receptors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Medullary Thyroid Cancer | Thyroid Gland Medullary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lu 177 | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lu 177
- description
- progressive metastatic medullary thyroid cancer
- interventionNames
- Radiation: Lu 177
Primary outcomes (1)
- measure
- Tumour Shrinkage
- timeFrame
- 6-8 months
- description
- RECIST 1.1 criteria
Secondary outcomes (1)
- measure
- Quality of life improvement
- timeFrame
- 6-8 months
- description
- SF 36 pre and post therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Medullary Thyroid Cancer * Doubling time calcitonin and CEA less than 6 months * Measurable disease by cross- sectional imaging * Irresectable tumors masses * \> 18 years of age Exclusion Criteria: * \< 18 years of age * Disease that can be treated with new surgical procedure * Stable disease
References
Publications (1)
- BACKGROUNDIten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR, Muller-Brand J, Walter MA. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702. doi: 10.1158/1078-0432.CCR-07-0935. PMID 18006770